Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2021 Jun 23;57(7):642.
doi: 10.3390/medicina57070642.

Evaluation of the Effectiveness of Helicobacter pylori Eradication Regimens in Lithuania during the Years 2013-2020: Data from the European Registry on Helicobacter pylori Management (Hp-EuReg)

Paulius Jonaitis  1 , Juozas Kupcinskas  1 , Olga P Nyssen  2   3 , Ignasi Puig  4   5 , Javier P Gisbert  2   3 , Laimas Jonaitis  1
Affiliations
Multicenter Study

Evaluation of the Effectiveness of Helicobacter pylori Eradication Regimens in Lithuania during the Years 2013-2020: Data from the European Registry on Helicobacter pylori Management (Hp-EuReg)

Paulius Jonaitis et al. Medicina (Kaunas). .

Abstract

Background and Objectives: The prevalence of H. pylori in Eastern Europe remains quite high; however, there is insufficient data on the eradication regimens and their effectiveness. Therefore, the objective of the study was to evaluate the diagnostic methods and treatment of H. pylori infection as well as their adherence to Maastricht V/Florence consensus during the years 2013-2020 in Lithuania. Materials and Methods: Sub-study of the "European Registry on H. pylori Management" (Hp-EuReg), international multicenter prospective non-interventional registry of the routine clinical practice. Lithuanian data from the years 2013-2020 were analyzed for effectiveness on a modified intention-to-treat (mITT) basis. 2000 adult patients, diagnosed with H. pylori infection, were included. Data were compared to the European Maastricht V guidelines. Results: Triple-therapy was used in 90% of the cases. In 91% of the first-line prescriptions, standard triple therapy (STT) was used. The most common second-line treatment was a combination of PPI, amoxicillin and levofloxacin (PPI+A+L) (47%). The overall effectiveness in 552 cases valid for analysis was 90% by mITT. In first-line treatment, the STT effectiveness was 90% and second-line treatment with PPI+A+L achieved 92% by mITT. Increasing overall H. pylori eradication rates were observed: from 72% in 2013 to more than 90% in 2018-2020, as well as a shift from 7 to 10-14 days treatments duration throughout 2013-2020. Conclusions: In Lithuania, the prescribed eradication regimens for H. pylori were in accordance with the international guidelines but diagnostic methods and treatment duration only partially met Maastricht V/Florence guidelines. The eradication effectiveness was improved progressively during the years 2018-2020, reaching ≥90% cure rates.

Keywords: Helicobacter pylori; Hp-EuReg; Lithuania; effectiveness; eradication.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Study flow chart. mITT—modified Intention-to-treat.
Figure 2
Figure 2
Trends in the H. pylori eradication rate during the years 2013–2020 (95% confidence intervals).
Figure 3
Figure 3
Duration of first and second-line treatments. Significant statistical differences have been found between treatment durations: χ2 test = 115.9; p < 0.001.
Figure 4
Figure 4
Trends of H. pylori eradication treatment duration during the years 2013–2020.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Malfertheiner P., Megraud F., O’morain C.A., Gisbert J.P., Kuipers E.J., Axon A.T., Bazzoli F., Gasbarrini A., Atherton J., Graham D.Y., et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66:6–30. doi: 10.1136/gutjnl-2016-312288. - DOI - PubMed
    1. Goh K.-L., Chan W.-K., Shiota S., Yamaoka Y. Epidemiology of Helicobacter pylori infection and public health implications. Helicobacter. 2011;16:1–9. doi: 10.1111/j.1523-5378.2011.00874.x. - DOI - PMC - PubMed
    1. Sjomina O., Pavlova J., Niv Y., Leja M. Epidemiology of Helicobacter pylori infection. Helicobacter. 2018;23(Suppl. S1):e12514. doi: 10.1111/hel.12514. - DOI - PubMed
    1. Jonaitis L., Pellicano R., Kupcinskas L. Helicobacter pylori and nonmalignant upper gastrointestinal diseases. Helicobacter. 2018;23(Suppl. S1):e12522. doi: 10.1111/hel.12522. - DOI - PubMed
    1. Moss S.F. The Clinical Evidence Linking Helicobacter pylori to Gastric Cancer. Cell Mol. Gastroenterol. Hepatol. 2017;3:183–191. doi: 10.1016/j.jcmgh.2016.12.001. - DOI - PMC - PubMed

Publication types